Substantial delivery challenges persist for agents that engage the STING pathway, a highly desirable cancer immunotherapy target. However, new tumor-penetrating lipid nanodiscs developed by the Irvine Lab outperformed previously designed nanoparticles in delivering STING-activating agents to induce tumor rejection and support immune memory against reintroduced tumor cells. This work was published in Nature Materials and supported in part by the Marble Center for Cancer Nanomedicine.